Zevra Therapeutics, Inc. (ZVRA): Total Liabilities
$130.07M
As of 2025-12-31
$85.06M
As of 2026-06-30
+47.9%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $130.07M | -6.1% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $138.46M | +25.3% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $110.46M | +174.6% | 2025-03-12, Balance as of period end |
| 2022-12-31 | $40.22M | n/c | 2024-04-01, Balance as of period end |
| 2021-12-31 | $5.82M | -92.5% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $77.62M | -8.6% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $84.96M | -8.9% | 2021-03-12, Balance as of period end |
| 2018-12-31 | $93.31M | -15.1% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $109.97M | +6.2% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $103.58M | +60.1% | 2018-03-30, Balance as of period end |
| 2015-12-31 | $64.71M | n/c | 2017-03-10, Balance as of period end |
| 2014-12-31 | $38.02M | n/a | 2016-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $130.07M | -6.1% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $78.03M | -37.2% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $305.93M | +3.9% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $23.85M | -11.7% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $20.65M | -27.6% |
| Xencor Inc (XNCR) | 2025-12-31 | $239.91M | -13.7% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $2.08B | +35.6% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $191.91M | -4.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
Compare ZVRA, ZYME, URGN, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗